|1.||Saif, Muhammad Wasif: 77 articles (12/2014 - 07/2005)|
|2.||Okusaka, Takuji: 53 articles (07/2015 - 12/2002)|
|3.||Furuse, Junji: 41 articles (10/2015 - 01/2005)|
|4.||Ueno, Hideki: 35 articles (07/2015 - 01/2005)|
|5.||Peters, G J: 35 articles (01/2014 - 01/2000)|
|6.||Abbruzzese, James L: 34 articles (04/2014 - 04/2002)|
|7.||Peters, Godefridus J: 32 articles (03/2015 - 02/2002)|
|8.||Georgoulias, V: 31 articles (04/2015 - 02/2000)|
|9.||Ikeda, Masafumi: 30 articles (07/2015 - 01/2005)|
|10.||Lawrence, Theodore S: 28 articles (10/2015 - 05/2002)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2009 - "Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. "
09/01/2012 - "Gemcitabine is currently the best treatment available for pancreatic cancer (PaCa); however, patients with the disease develop resistance to the drug over time. "
05/01/2011 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but causes high toxicity. "
12/01/2010 - "Most pancreatic cancer patients are diagnosed at the advanced stages, and no therapy is superior to gemcitabine alone. "
04/15/2007 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease develops resistance to the drug over time. "
01/01/2012 - "Therefore, a combination therapy of THU and gemcitabine is considered to be a potential and promising treatment for tumors with highly expressed CDA. "
10/15/2010 - "The squalenoylation drug delivery strategy might, therefore, dramatically improve the efficacy of gemcitabine on transporter-deficient resistant cancer in the clinical context."
11/01/2008 - "Gemcitabine fulfills all requirements as an alternative agent in treating BCG failure patients with low adverse events, well tolerated, and highly effective in reducing tumor recurrences."
01/01/2008 - "Gemcitabine fulfils all requirements as an alternative agent, in treating BCG failure patients with low adverse events, is well tolerated and highly effective in reducing tumor recurrences."
08/01/2006 - "The significantly improved therapeutic outcome of animals receiving the triple therapy was attributed to multiple factors, including most likely improved FMG expression throughout the tumor and enhanced sensitivity of the tumor cells to gemcitabine by adenoviral gene products but also FMG expression. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/05/2005 - "Although gemcitabine is a potent therapeutic agent in the treatment of human non-small cell lung cancer (NSCLC), resistance to gemcitabine is common. "
07/01/1999 - "Following the diagnosis of non-small cell lung carcinoma and subsequent treatment with gemcitabine (a second-line chemotherapeutic agent), a significant reduction in both tumour mass and mucosal blistering was observed. "
03/01/2013 - "When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer."
05/01/1996 - "As the efficacy of gemcitabine in non-small cell lung cancer was equivalent when using both regimens, the better tolerated and more easily administered once-weekly schedule is recommended."
05/01/2010 - "The combination of gemcitabine and S-1 was determined to be feasible and effective for advanced non-small cell lung cancer. "
|4.||Breast Neoplasms (Breast Cancer)
04/01/2003 - "Data from phase II clinical studies suggest that gemcitabine/anthracycline combinations are relatively effective in first- or second-line therapy for women with locally advanced and metastatic breast cancer. "
04/01/2005 - "Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients."
12/01/2013 - "Our study is the first to demonstrate the pleiotropic effects of Gemcitabine and Gemcitabine-loaded nanoparticles in breast cancer, and opens the door for a novel treatment for breast cancer patients."
02/01/2010 - "This phase II study was designed to assess the efficacy of Gemcitabine (GEM) and PEM given in a novel schedule in metastatic breast cancer (MBC) patients. "
07/01/2015 - "The aim of the present study was to show that treatment of low HER2-expressing breast cancer cells with gemcitabine (GEM) enhanced HER2 expression using RT-qPCR, immunoblot and flow cytometric analysis. "
01/01/2012 - "This study aimed to determine whether the treatment of pancreatic carcinoma can be defined on the basis of the expression of genes involved in gemcitabine metabolism and whether combination treatment is more effective than conventional treatment. "
09/01/2007 - "Here, a murine pancreatic carcinoma model was used to investigate whether combination with gemcitabine increases therapeutic efficacy of DC-based vaccination. "
04/01/2010 - "Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment."
09/01/2008 - "The present study was carried out with the objective of assessing the feasibility and efficacy of low dose gemcitabine as radiosensitizer when used during radical radiotherapeutic management of patients with locally advanced head and neck carcinomas. "
06/15/2003 - "The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma. "
|9.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)